[1]CurrentPatentAssignee:NERVIANOMEDICALSCIENCESS.R.L.-WO2004/104007,2004,A1Locationinpatent:Page179-180;187
[1]CurrentPatentAssignee:NERVIANOMEDICALSCIENCESS.R.L.-WO2004/104007,2004,A1Locationinpatent:Page182-183
[1]Locationinpatent:experimentalpartBrasca,MariaGabriella;Amboldi,Nadia;Ballinari,Dario;Cameron,Alexander;Casale,Elena;Cervi,Giovanni;Colombo,Maristella;Colotta,Francesco;Croci,Valter;D'Alessio,Roberto;Fiorentini,Francesco;Isacchi,Antonella;Mercurio,Ciro;Moretti,Walter;Panzeri,Achille;Pastori,Wilma;Pevarello,Paolo;Quartieri,Francesca;Roletto,Fulvia;Traquandi,Gabriella;Vianello,Paola;Vulpetti,Anna;Ciomei,Marina[JournalofMedicinalChemistry,2009,vol.52,#16,p.5152-5163]
[1]CurrentPatentAssignee:NERVIANOMEDICALSCIENCESS.R.L.-WO2010/125004,2010,A1Locationinpatent:Page/Pagecolumn14
[1]CurrentPatentAssignee:NERVIANOMEDICALSCIENCESS.R.L.-WO2010/125004,2010,A1Locationinpatent:Page/Pagecolumn13-14
Title: Phase I study of the safety, tolerability and pharmacokinetics of PHA-848125AC, a dual tropomyosin receptor kinase A and cyclin-dependent kinase inhibitor, in patients with advanced solid malignancies.
Journal: Investigational new drugs 20121201
Title: Down-regulation of the PTTG1 proto-oncogene contributes to the melanoma suppressive effects of the cyclin-dependent kinase inhibitor PHA-848125.
Journal: Biochemical pharmacology 20120901
Title: Dual targeting of CDK and tropomyosin receptor kinase families by the oral inhibitor PHA-848125, an agent with broad-spectrum antitumor efficacy.
Journal: Molecular cancer therapeutics 20100801
Title: The cyclin-dependent kinase inhibitor PHA-848125 suppresses the in vitro growth of human melanomas sensitive or resistant to temozolomide, and shows synergistic effects in combination with this triazene compound.
Journal: Pharmacological research 20100501
Title: Efficacy of PHA-848125, a cyclin-dependent kinase inhibitor, on the K-Ras(G12D)LA2 lung adenocarcinoma transgenic mouse model: evaluation by multimodality imaging.
Journal: Molecular cancer therapeutics 20100301
Title: Identification of N,1,4,4-tetramethyl-8-{[4-(4-methylpiperazin-1-yl)phenyl]amino}-4,5-dihydro-1H-pyrazolo[4,3-h]quinazoline-3-carboxamide (PHA-848125), a potent, orally available cyclin dependent kinase inhibitor.
Journal: Journal of medicinal chemistry 20090827
Title: Caporali S, Alvino E, Levati L, Esposito AI, Ciomei M, Brasca MG, Del Bufalo D, Desideri M, Bonmassar E, Pfeffer U, D'Atri S.Down-regulation of the PTTG1 proto-oncogene contributes to the melanoma suppressive effects of the cyclin-dependent kinase inhibitor PHA-848125.Biochem Pharmacol. 2012 Sep 1;84(5):598-611.
Title: Albanese C, Alzani R, Amboldi N, Avanzi N, Ballinari D, Brasca MG, Festuccia C, Fiorentini F, Locatelli G, Pastori W, Patton V, Roletto F, Colotta F, Galvani A, Isacchi A, Moll J, Pesenti E, Mercurio C, Ciomei M.Dual targeting of CDK and tropomyosin receptor kinase families by the oral inhibitor PHA-848125, an agent with broad-spectrum antitumor efficacy.Mol Cancer Ther. 2010 Aug;9(8):2243-54.
Title: Degrassi A, et al.Efficacy of PHA-848125, a cyclin-dependent kinase inhibitor, on the K-Ras(G12D)LA2 lung adenocarcinoma transgenic mouse model: evaluation by multimodality imaging.Mol Cancer Ther. 2010 Mar;9(3):673-81.
Title: Brasca, M.G., et al. Identification of N,1,4,4-tetramethyl-8-{-(4-methylpiperazin-1-yl)phenylamino}-4,5-dihydro-1H-pyrazolo,3-hquinazoline-3-carboxamide (PHA-848125), a potent, orally available cyclin dependent kinase inhibitor. J. Med. Chem. 52(16), 5152-5163 (2009).
